DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Every review source we could verify for Mochi Health, and an honest read on what each one measures. No aggregate score — we have no way to source one, and an invented number would look measured.
compounded telehealth
Read the reviews yourself
Skews positive. Companies invite reviews right after purchase — before anyone has hit a refill, a dose escalation, or a cancellation. You are mostly reading week-one enthusiasm.
Read it for: Onboarding and shipping speed. Discount anything it says about long-term experience.
Unfiltered and unsolicited, but self-selected: people post when something goes wrong or unusually right, and the compounding subs skew ideological about FDA-approved vs compounded.
Read it for: Month 3+ experience — supply gaps, dose-escalation problems, what the vial actually looked like. The one place long-term users talk.
High noise floor and a weak verification process compared with the others.
Read it for: Corroborating a pattern you already saw on BBB — not for forming a first impression.
Read these alongside the documented regulatory record — a Washington State licence restriction on Mochi's own compounding pharmacy tells you more about what is in the vial than any star rating will. See the record on the verification page below.
LoseLab publishes no aggregate review score. We have no verified way to source one — and a number we made up would look measured, which is worse than saying nothing. What we can give you is every real review source and an honest read on what each one is worth.
A star rating measures how customers felt. These measure what a regulator or a court found. When the two disagree, the second one is the one that bears on what is in the vial.
Eli Lilly sued Mochi over its marketing of compounded tirzepatide (federal Lanham Act plus California unfair-competition claims). A federal judge later declined to throw out Lilly's core claims, so the case is proceeding. The allegations are unproven — read the reporting and decide for yourself.
CNBC — Lilly sues telehealth sellers of compounded tirzepatideWashington regulators restricted the license of Aequita, the Kirkland compounding pharmacy owned by Mochi, following whistleblower allegations that unlicensed workers handled patient medications and that cold-chain shipments were packed with frozen children's popsicles instead of medical-grade ice. This one bears on the vial itself, not just the marketing.
Partnership for Safe MedicinesSkews positive. Companies invite reviews right after purchase — before anyone has hit a refill, a dose escalation, or a cancellation. You are mostly reading week-one enthusiasm.
Read it for: Onboarding and shipping speed. Discount anything it says about long-term experience.
Unfiltered and unsolicited, but self-selected: people post when something goes wrong or unusually right, and the compounding subs skew ideological about FDA-approved vs compounded.
Read it for: Month 3+ experience — supply gaps, dose-escalation problems, what the vial actually looked like. The one place long-term users talk.
High noise floor and a weak verification process compared with the others.
Read it for: Corroborating a pattern you already saw on BBB — not for forming a first impression.
Reviews cannot tell you who will actually write your prescription. That you can check yourself, free, in about two minutes — whether Mochi Health names a clinical lead, and how to run any prescriber through the NPI Registry, ABMS board certification, and their state medical board.
Mochi Health verification record